Wang et al. developed an intranasal anti-EphA3 functionalized AuNPs for temozolomide delivery to glioblastoma [12] which was shown to prolong the median survival time and increase apoptosis compared to free drug. This evidence concerns the gene EPHA3 and glioblastoma.